Effects of morphine on histamine release from two cell lines of canine mast cell tumor and on plasma histamine concentrations in dogs with cutaneous mast cell tumor

Taylor L. Curley DVM
Douglas H. Thamm VMD
Sam W. Johnson DVM
Pedro Boscan DVM, PhD

From the Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80521.

Address correspondence to Dr. Boscan (pboscan@colostate.edu).

OBJECTIVE
To determine the effects of morphine on histamine release from 2 canine mast cell tumor (MCT) cell lines and on plasma histamine concentrations in dogs with cutaneous MCTs.

ANIMALS
10 dogs with cutaneous MCT and 10 dogs with soft tissue sarcoma (STS).

PROCEDURES
The study consisted of 2 phases. First, 2 canine MCT cell lines were exposed to 3 pharmacologically relevant morphine concentrations, and histamine concentrations were determined by an ELISA. Second, dogs with MCT or STS received 0.5 mg of morphine/kg, IM, before surgery for tumor excision. Clinical signs, respiratory rate, heart rate, arterial blood pressure, rectal temperature, and plasma histamine concentrations were recorded before and 5, 15, 30, and 60 minutes after morphine administration but prior to surgery. Data were compared by use of a 2-way ANOVA with the Sidak multiple comparisons test.

RESULTS
In the first phase, canine MCT cell lines did not release histamine when exposed to pharmacologically relevant morphine concentrations. In the second phase, no differences were noted for heart rate, arterial blood pressure, and rectal temperature between MCT and STS groups. Plasma histamine concentrations did not significantly differ over time within groups and between groups.

CONCLUSIONS AND CLINICAL RELEVANCE
No significant changes in histamine concentrations were noted for both in vitro and in vivo study phases, and no hemodynamic changes were noted for the in vivo study phase. These preliminary results suggested that morphine may be used safely in some dogs with MCT.

Materials and Methods

Cell lines and conditions
Two canine MCT cell lines, C2 and BR, were maintained in C10 media (RPMI 1640 culture medium [Lonza Group Ltd] supplemented with heat-inactivated 10% fetal bovine serum [Peak Serum Inc] and a solution mixture [Cellgro] of 1X minimum essential medium, 2mM L-glutamine, 1mM sodium pyruvate, 1X nonessential amino acid solution, and 1X antimicrobial [bacteria and fungi] solution) and placed in a
humidified incubator with 5% CO₂ at 37 °C. Cell lines were confirmed to be of canine origin by use of a multispecies multiplex PCR assay and authenticated with short-tandem repeated analysis as described. The 2 X 10⁶ C2 or BR cells were placed in 500 µL of Tyrode buffer (Sigma-Aldrich) and incubated for 1 hour at 37 °C in the presence of 1, 100, or 1,000 ng of morphine/mL in duplicate. Mastoparan (Cayman Chemical; 25µM) served as the positive control, and Tyrode buffer alone (untreated) served as the negative control. After incubation, the reactions were stopped with 15-minute incubation on ice, after which the supernatants were removed and stored at −80 °C until analysis. Samples were thawed, and histamine concentrations were measured in duplicate by use of an ELISA (Immunotech). The assay’s sensitivity was 0.05 ng/mL and had been validated for histamine determination in dogs.

**Clinical trial**

Written informed consent by dog owners was obtained for all dogs included in the study, and the Colorado State University Institutional Animal Care and Use Committee and Veterinary Teaching Hospital Clinical Review Board approved the study. Inclusion criteria were a confirmed diagnosis of MCT or soft tissue sarcoma (STS) via microscopic examination of cells collected through a fine-needle aspirate (cytology) or of tissue collected through a biopsy (histology), presentation for MCT or STS excision, > 1 year of age, and medical stability based on history, physical examination, CBC, and serum biochemical analyses. Exclusion criteria were dogs that had a history of hypersensitivity reactions including those to food and environmental allergens, were pregnant, were presented for an emergency situation, had a history of respiratory or cardiovascular failure, had current or recent corticosteroid treatment (< 72 hours before presentation), had chemotherapy in the week before presentation, or had been administered antihistamine drugs (H1 and H2 receptor antagonists) within the previous 3 days. To achieve a study power of 80%, 10 dogs each from the MCT and STS groups were required to identify changes in plasma histamine concentration of 0.5 ng/mL with an α of 0.05. Ten dogs with confirmed cutaneous MCT and 10 dogs with confirmed STS were included in the clinical trial.

All dogs were premedicated with 0.5 mg of morphine/kg IM. A 20- or 22-gauge catheter (Becton, Dickinson and Co) was placed. Anesthesia was induced with propofol (2 to 8 mg/kg, IV), to effect and was maintained with isoflurane. Acepromazine was avoided because of its antihistamine effects. Respiratory rate, heart (pulse) rate, blood pressure, rectal temperature, incidence of emesis, plasma histamine concentration, and any other observed abnormality (eg, arrhythmia, diarrhea, or behavior change) were recorded before and 5, 15, 30, and 60 minutes after morphine administration but prior to surgery. Respiratory rate was determined by observing chest excursions, heart (pulse) rate was determined with palpation of the femoral pulse, noninvasive arterial blood pressure was obtained with an oscillometric blood pressure monitor (VetTRENDS), and rectal temperature was obtained with a thermometer (DTR-1221A; iProven). Plasma histamine concentrations were measured from 3 mL of blood collected from a cephalic or saphenous vein catheter. Blood samples were collected in glass tubes containing EDTA (BD Vacutainer; Becton, Dickinson and Co), and refrigerated immediately after collection until centrifugation (1,500 X g for 15 minutes at 4 °C). Plasma was stored at −80 °C until analysis with an ELISA (LDN).

**Statistical analysis**

In vitro plasma histamine concentrations were compared among conditions (1, 100, and 1,000 ng of morphine/mL, positive control, and negative control) by use of an ANOVA with the Tukey post hoc test. In vivo patient variables (age, sex, and body weight) were reported and compared by use of descriptive statistics. Group data were analyzed for distribution normality with the Shapiro-Wilk test. Normally distributed data are presented as mean ± SD, and non-normally distributed data are presented as median and range. Data between groups (MCT vs STS) were compared by use of a 2-way ANOVA followed by the Sidak multiple comparison test. Continuous variables were compared by use of a 1-way or 2-way ANOVA and then with the Tukey post hoc test. Statistical analyses were performed with commercial software (Prism version 9; GraphPad Software Inc). Values of P < 0.05 were considered significant.

**Results**

**Cell lines and conditions**

After both canine MCT cell lines were exposed to morphine, histamine concentrations did not significantly (P = 0.48 for BR cell line and P = 0.76 for C2 cell line) differ from histamine concentrations for the untreated (negative control) cell lines (Figure 1).

**Clinical trial**

Intramuscular administration of morphine resulted in a significant (P < 0.05) decrease in heart (pulse) rate and rectal temperature over time, compared with baseline (before morphine administration), in MCT and STS groups (Figures 2 and 3). No consistent significant changes in arterial blood pressure were observed, although systolic and diastolic arterial blood pressure decreased over time (Figure 4). All 10 dogs in the STS group and 9 of 10 dogs in the MCT group were panting before morphine administration. After morphine administration, 9 and 8 dogs in STS and MCT groups, respectively, continued to pant. Hemodynamic parameters remained within the expected values for normal dogs. When data were compared...
between groups, no significant differences in heart rate ($P = 0.62$), rectal temperature ($P = 0.87$), or systolic ($P = 0.19$) and diastolic arterial blood pressure ($P = 0.21$) were observed over time. Morphine induced emesis in 6 dogs in the STS group and 3 dogs in the MCT group.

The median (range) plasma histamine concentrations at baseline (before morphine administration) were 0.75 ng/mL (0.2 to 3.3 ng/mL) and 0.4 ng/mL (0 to 1.0 ng/mL) for STS and MCT groups, respectively, and did not significantly differ ($P = 0.10$) between groups (Figure 5). Morphine did not significantly affect histamine concentrations over time within each group ($P = 0.76$ for STS; $P = 0.67$ for MCT) and between groups ($P = 0.76$; Figure 6). Dogs in the MCT group were more likely to experience a 3-fold increase in plasma histamine concentration after morphine administration, although this difference was not significant ($P = 0.14$).

Surgical manipulation of the MCT stimulated histamine release in 1 dog. By the 60-minute time point, surgery had been initiated in no dogs from the STS group and 1 dog from MCT group. Data for this dog at 60 minutes were excluded for all calculations because of the possibility that manipulation of the MCT induced release of histamine. In this dog, plasma histamine concentration increased to

---

**Figure 1**—In vitro supernatant histamine concentrations from canine BR- and C2-mast cell tumor (MCT) cell lines after exposure to 1, 100, or 1,000 ng of morphine/mL, 25μM mastoparan (positive control [PC]), or Tyrode buffer (negative control; untreated). *Indicates $P < 0.05$ for comparison between PC and untreated cells.

**Figure 2**—Changes in heart (pulse) rate (percentage of baseline, with baseline considered as 100%) from time 0 (before morphine administration) and 5, 15, 30, and 60 minutes after morphine administration (0.5 mg/kg, IM) but prior to surgery for 10 dogs with MCT and 10 dogs with soft tissue sarcoma (STS). For each time point after morphine administration, mean (middle line) and SD (whiskers) are shown. *Indicates $P < 0.05$ between time points within each group.

**Figure 3**—Changes in rectal temperature (percentage of baseline, with baseline considered as 100%) from time 0 (before morphine administration) and 5, 15, 30, and 60 minutes after morphine administration but prior to surgery. See Figure 2 for key.

**Figure 4**—Changes in systolic (A) and diastolic (B) arterial blood pressure (percentage of baseline, with baseline considered as 100%) from time 0 (before morphine administration) and 5, 15, 30, and 60 minutes after morphine administration but prior to surgery. See Figure 2 for key.
22.1 ng/mL from the pretreatment concentration of 0.1 ng/mL.

No complications were observed in any dog during anesthesia, surgery, or the recovery period. All dogs were discharged from the hospital the day after surgery.

Discussion

In the present study, morphine did not induce histamine release from canine MCT cell lines, and morphine administered IM to dogs with STS or MCT did not induce significant changes in plasma histamine concentrations. Changes in hemodynamic parameters were as expected for morphine and were not suggestive of histamine release, MCT degranulation, or anaphylaxis.

Dogs in the MCT group had lower baseline plasma histamine concentrations and were more likely to have a relative 3-fold increase in plasma histamine concentrations after morphine administration, compared with concentrations for dogs in the STS group. However, baseline histamine concentrations in both groups were within the range for healthy dogs (0.1 to 1 ng/mL) and healthy people. Furthermore, in the present study, plasma histamine concentrations did not reach 10 ng/mL, a concentration expected to cause clinical signs induced by histamine. The relative increase in histamine concentration in the MCT group was possibly due to the lower baseline histamine concentration in this group than in the STS group.

Histamine release and high plasma histamine concentrations are considered the core for anaphylactic reactions in human and veterinary patients. Plasma histamine concentrations correlate with illness and death during the pathophysiologic processes that encompass systemic hypotension. In people, plasma histamine concentrations > 2 ng/mL can induce cardiovascular changes and subsequent clinical signs. For dogs, fewer studies exist and a variable range of plasma histamine concentrations have been described. In a previous study, a plasma histamine concentration of 300 ng/mL was necessary to induce systemic hypotension in some dogs, although other dogs had localized flushing of the skin and mucus membranes. Other studies have shown little differences between species. For example, Owen et al reported that continuous infusion of histamine decreases arterial blood pressure in people, dogs, and cats in a similar dose-dependent fashion. However, plasma histamine concentrations do not always correlate with systemic hypotension in people.

In the present study, morphine was administered IM. In previous studies with dogs, significantly higher plasma histamine concentrations were reported following IV administration of morphine and higher doses of morphine. It was unknown whether IV (vs IM) administration or administration of morphine at higher doses (vs those used in the present study) would induce higher plasma histamine concentrations in the dogs of the present study. Only sedation was observed after morphine administration despite a study that indicates neuroexcitation in addition to sedation can occur. The difference among studies may be attributed to the dose, rate of administration, or route of administration.

The pathway by which morphine induces histamine release is not well understood. Reports indicate that it may not be mediated through agonism of mu-opioid receptors or antagonism by naloxone. Thus, the manner by which histamine is released from MCTs may be more complex than expected.

Unauthenticated | Downloaded 12/19/21 06:11 PM UTC
mine release may depend on the route and speed of morphine administration, morphine dose; and stage (tumor burden) of MCT. These aspects were not considered in the present study.

The greatest increase in plasma histamine concentration in the present study was noted for the dog that underwent surgical manipulation of its MCT 60 minutes after morphine administration. This finding was not surprising because MCT degranulation has been reported during tumor manipulation, with histamine release subsequently causing hypotension, coagulopathies, and local tumor edema and inflammation.18,19 Studies are necessary to better understand the risk of adverse effects secondary to histamine release from MCTs during surgery.

One important study limitation was that only 10 dogs with MCT and 2 canine MCT cell lines were evaluated. A larger population size is imperative to confirm that 0.5 mg of morphine/kg, IM, does not induce significant histamine release in all or most dogs with MCT. Second, each dog had a relatively small-sized MCT; therefore, the effect morphine has on larger, more aggressive, or disseminated MCTs is unknown. Therefore, the results of the present study were considered preliminary. Third, blood samples were obtained from peripheral veins, and samples obtained from peripheral veins are not considered as the optimal sample type to determine plasma histamine concentrations.15,36 Fourth, an ELISA was used to determine histamine concentrations, and although it is commonly used, it may have suboptimal sensitivity, compared with other assays.15,36 Fifth, plasma histamine concentrations were determined 5, 15, 30, and 60 minutes following IM administration of morphine. Histamine concentrations could have differed at other time points. Lastly, only morphine was evaluated, such that additional studies are necessary to determine histamine concentrations after exposure to other opioids.

In conclusion, no significant changes in plasma histamine concentrations and hemodynamic parameters were observed in dogs with STS or MCT after IM administration of morphine. Rather, hemodynamic changes in both groups were attributed to morphine-induced sedation. These preliminary results suggested that morphine may be used safely in some dogs with MCT.

Acknowledgments

Funded by the Young Investigator Award program, College of Veterinary Medicine and Biomedical Sciences, Colorado State University.

The CR and BR cell lines used in the study were provided by Dr. Warren Gold, University of California-San Francisco, San Francisco, California.

The authors declare that there were no conflicts of interest.

The authors thank Barbara Rose for technical assistance.

References